 Wysłany: Sob 4:40, 19 Mar 2011 Temat postu: GHD glätteisen sdd tff rrb qcv |
|
| HMG-CoA reductase inhibitor treatment of hypercholesterolemia
j2 :1212-12l3 .11. YamamotoA, SudoH, EndoA. TherapeuticeffectsofML a 238Binprimaryhypercholesterolemia. AtherosclerosiS198OI35 :259-286 .12. GrundySM, VegaGL. Influenceofmevlnolinonmetabolismoflowdensitylipoproteinsinprimarymoderatehypercholesterolemia. JLipidReS1985t26ll464-1475.13. GargA, GrundySM. Lovastatinforloweringcholesterollevelsinnoninsulin-dependentdiabetesmellitus. NEnglJMed1988I318'81-86 .14. WeisgraberKH,tory burch reva, RallSCJr,adidas scarpe, MahleyRW. HumanEapoprotelnhetero-geneity; cysteine-arginineinterchangeSintheaminoacidsequeneeoftheapo-Eisoforms. JBiolChem198l | 256:9077-9083.15. GrundySM. PMhogenesisofhyperlip0proteinemia. JLipidReS1984j25El6l1-1618.16. VegaGL, EastC,herve leger uk, GrundySM. Lovastatintherapyinfamilialdys-betalip0pr0teinemi; effectsO12kineticsofap0lip0pr0teinB. Athero-sclerosis1988t70; l3l-l43.17. HoegJM,supra shoes outlet, MaherMB,GHD glätteisen, ZechLA, eta1. EffectivenessofmevinolinOilplasmalipoproteinconcentrationsintypeIIhyperlipoprotelnemia. AmJCardioll986157 :933-939. t8. GinsbergHN, LeNA, ShortMP, eta1. Suppressionofapolipo-proteinBproductionduringtreatmentofeholesterylesterstoragediseasewithlovastatin, implicationsforregulationofapo1ipopr0teinBsynthesis. JCllnInvest1987I80; 1692-1697.19. TengB, SnidermanAD, SoutarAK, eta1. Metabolicbasisofhyperapobeta1ip0pr. teinemla: tumoverofap0lipopf0teinBinlowdensitylipoproteinanditsPreCursorsandsubfractionscomparedwithnormalandfamilialhypercholesterolemia. JCli Ⅱ lavestl986t77 :663-672 .20. TobertJA. Newdevelopmentsinlipid-loweringtherapy; theroleofinhibitorsofhydroxymethylglutaryl-coenzymeAreductase. Circula-tionl987t76 :534 - 538. J5T |
|
